Cipla enters into agreement with Eli Lilly and Company

23 Oct 2025 Evaluate

Cipla has entered into agreement with Eli Lilly and Company (India) (Lilly) to distribute and promote tirzepatide in India under a second brand name, Yurpeak. Under the agreement, Cipla has the rights to distribute and promote Yurpeak--the second brand of tirzepatide in India. This strategic agreement aims to expand the availability of tirzepatide by enabling broader access across the country beyond cities where Lilly already has an established presence. Lilly will manufacture and supply Yurpeak to Cipla, and the price will be the same as Mounjaro.

Yurpeak (tirzepatide) will be available in the KwikPen presentation, a multi-dose single-patient-use prefilled pen. Each pen contains four fixed doses, administered once weekly. The pen will be available in six dose strengths: 2.5 mg, 5 mg, 7.5 mg, 10 mg, 12.5 mg, or 15 mg, allowing healthcare professionals to personalize treatment plans to better suit individual patient needs. 

Cipla is a global pharmaceutical company which uses cutting edge technology and innovation to meet the everyday needs of all patients.


Cipla Share Price

1397.95 -36.65 (-2.55%)
16-Jan-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1669.20
Dr. Reddys Lab 1175.55
Cipla 1397.95
Zydus Lifesciences 867.80
Lupin 2176.25
View more..
Register Now to get our Free Newsletter & much more!

© 2026 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×